Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A former labor and delivery nurse, Lindy Sledge, 62, lives with her family in Franklin, Kentucky. She has mantle cell lymphoma.
Here are latest arrivals approved by the Food and Drug Administration.
Tecartus led to durable remission in a majority of participants in a Phase II study.
KTE-X19 led to durable remission in a majority of study participants.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
“There’s nothing that we can’t face together. We’ll never walk alone.”
Safety profile suggests patients receiving the new immunotherapy may not need to be hospitalized.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.